| Ceritinib in ALK-rearranged non–small-cell lung cancer AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ... N Engl j med 370, 1189-1197, 2014 | 1739 | 2014 |
| First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ... The Lancet 389 (10072), 917-929, 2017 | 1051 | 2017 |
| Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates Y Simoni, E Becht, M Fehlings, CY Loh, SL Koo, KWW Teng, JPS Yeong, ... Nature 557 (7706), 575-579, 2018 | 893 | 2018 |
| Isolation and retrieval of circulating tumor cells using centrifugal forces HW Hou, ME Warkiani, BL Khoo, ZR Li, RA Soo, DSW Tan, WT Lim, J Han, ... Scientific reports 3 (1), 1259, 2013 | 811 | 2013 |
| A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer KP Ng, AM Hillmer, CTH Chuah, WC Juan, TK Ko, ASM Teo, ... Nature medicine 18 (4), 521-528, 2012 | 631 | 2012 |
| Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells ME Warkiani, G Guan, KB Luan, WC Lee, AAS Bhagat, PK Chaudhuri, ... Lab on a Chip 14 (1), 128-137, 2014 | 589 | 2014 |
| Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ... Journal of thoracic oncology 13 (9), 1248-1268, 2018 | 544 | 2018 |
| Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer J Wolf, T Seto, JY Han, N Reguart, EB Garon, HJM Groen, DSW Tan, ... New England Journal of Medicine 383 (10), 944-957, 2020 | 483 | 2020 |
| Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020 | 481 | 2020 |
| Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ... The lancet oncology 17 (4), 452-463, 2016 | 467 | 2016 |
| Efficacy of Selpercatinib in RET-Altered Thyroid Cancers LJ Wirth, E Sherman, B Robinson, B Solomon, H Kang, J Lorch, F Worden, ... New England Journal of Medicine 383 (9), 825-835, 2020 | 429 | 2020 |
| Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency Y Simoni, M Fehlings, HN Kløverpris, N McGovern, SL Koo, CY Loh, ... Immunity 46 (1), 148-161, 2017 | 405 | 2017 |
| Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ... The Lancet Oncology 21 (2), 261-270, 2020 | 319 | 2020 |
| Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes A Drilon, ZI Hu, GGY Lai, DSW Tan Nature reviews Clinical oncology 15 (3), 151-167, 2018 | 290 | 2018 |
| Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus G Curigliano, S Banerjee, A Cervantes, MC Garassino, P Garrido, ... Annals of Oncology 31 (10), 1320-1335, 2020 | 258 | 2020 |
| Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor … YL Wu, L Zhang, DW Kim, X Liu, DH Lee, JCH Yang, MJ Ahn, ... Journal of Clinical Oncology 36 (31), 3101-+, 2018 | 240 | 2018 |
| Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma T Tan, WT Lim, KW Fong, SL Cheah, YL Soong, MK Ang, QS Ng, D Tan, ... International Journal of Radiation Oncology* Biology* Physics 91 (5), 952-960, 2015 | 226 | 2015 |
| The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation–Positive Non–Small cell lung cancer: Status in 2016 DSW Tan, SS Yom, MS Tsao, HI Pass, K Kelly, N Peled, RC Yung, ... Journal of Thoracic Oncology 11 (7), 946-963, 2016 | 202 | 2016 |
| Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development DSW Tan, GV Thomas, MD Garrett, U Banerji, JS De Bono, SB Kaye, ... The Cancer Journal 15 (5), 406-420, 2009 | 202 | 2009 |
| Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head … NG Iyer, DSW Tan, VKM Tan, W Wang, J Hwang, NC Tan, R Sivanandan, ... Cancer 121 (10), 1599-1607, 2015 | 201 | 2015 |
